Clinical trials: Methotrexate
Rheumatoid Arthritis
Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )
The purpose of this study is to asses the long term efficacy, safety and immunogenicity of ENERCEPTAN® in combination with Methotrexate for the treatment of patients with rheumatoid arthritis up to 104 weeks
- Trial name
- NCT03403140
- Testing
- Etanercept
- Where
- Argentina
- Volunteers
- 141 people
- Sponsor
- Gema Biotech S.A.
Rheumatoid Arthritis
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.
- Trial name
- NCT04413617
- Testing
- PF-06650833, PF-06651600, Tofacitinib
- Where
- 144 sites in Bulgaria, Canada and 8 more
- Volunteers
- 460 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Applications for Methotrexate Optimization in Rheumatoid Arthritis
The goal of this study is to enable the study sponsor to assess the impact of a marketed or validated blood test has on physicians' clinical treatment decision making when treating RA patients who have been taking methotrexate.
- Trial name
- AMORA (NCT01038349)
- Testing
- Avise PG - Diagnostic test
- Volunteers
- 256 people
- Sponsor
- Cypress Bioscience, Inc.
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
This randomized, double-blind, parallel group study will assess the safety, disease remission, and prevention of structural joint damage in patients with early moderate to severe rheumatoid arthritis treated with tocilizumab as…
- Trial name
- NCT01007435
- Testing
- Tocilizumab, Methotrexate
- Where
- 236 sites in United States, Argentina and 34 more
- Volunteers
- 1,162 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
This is a 12 week study that will evaluate the efficacy and safety of the 11 mg tofacitinib modified release tablet taken once a day in patients with rheumatoid arthritis who continue taking methotrexate.
- Trial name
- NCT02281552
- Testing
- Tofacitinib
- Where
- 36 sites in Japan
- Volunteers
- 209 people
- Sponsor
- Pfizer
Psoriasis
Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.
- Trial name
- CLEAR (NCT02196701)
- Testing
- Adalimumab, Methotrexate
- Volunteers
- 46 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
This single arm study will evaluate the efficacy and safety of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response to one or more anti-TNF therapies.
- Trial name
- NCT00462345
- Testing
- rituximab, Methotrexate, Corticosteroid or NSAID
- Where
- 4 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis
The objective of this study is to compare in Chinese subjects with rheumatoid arthritis (RA) the efficacy and safety in this subject population of 50 mg once-weekly injections of etanercept versus placebo in subjects receiving…
- Trial name
- NCT00443950
- Testing
- Etanercept
- Where
- 6 sites in China
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate…
- Trial name
- NCT01235507
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Bosnia and Herzegovina
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an…
- Trial name
- NCT04909801
- Testing
- Abatacept, Adalimumab, Methotrexate
- Where
- 75 sites in United States, Argentina and 12 more
- Volunteers
- 338 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
This 3 arm study assessed the efficacy of rituximab (MabThera®/Rituxan®) in the prevention of progression of structural joint damage in participants with active rheumatoid arthritis who had an inadequate clinical response to…
- Trial name
- SCORE (NCT00578305)
- Testing
- Rituximab, Methylprednisolone, Methotrexate
- Where
- 60 sites in Argentina, Brazil and 17 more
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy.
- Trial name
- IMAGE (NCT00299104)
- Testing
- folate, methotrexate, methylprednisolone
- Volunteers
- 755 people
- Sponsor
- Genentech, Inc.
Gout
A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.
To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the…
- Trial name
- NCT06298071
- Testing
- SIBP-R002, Methotrexate
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Institute Of Biological Products
Rheumatoid Arthritis
Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis
A 12-week with possible extension, phase II study to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day in combination with methotrexate, in treatment of patients with active rheumatoid arthritis refractory to standard…
- Trial name
- NCT00913432
- Testing
- masitinib
- Volunteers
- 20 people
- Sponsor
- AB Science
Rheumatoid Arthritis
A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis
This study is being carried out to investigate if AZD5672 is effective in treating Rheumatoid Arthritis (RA) and if so how it compares to placebo (a substance which does not have any action) and etanercept (a medicine already…
- Trial name
- ESCAPE (NCT00713544)
- Testing
- AZD5672, Etanercept
- Where
- 49 sites in Bulgaria, Colombia and 12 more
- Volunteers
- 373 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
Approximately 108 subjects will be randomized in 2 arms in 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks.
- Trial name
- NCT06590090
- Testing
- Natrunix 400 mg, Methotrexate (MTX)
- Volunteers
- 108 people
- Sponsor
- XBiotech, Inc.
Psoriatic Arthritis
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
Randomized, double-blind, 24-week study of patients with psoriatic arthritis comparing alefacept + methotrexate (MTX) vs. placebo + MTX followed by a 24-week open-label extension with only alefacept + MTX treatment.
- Trial name
- NCT00659412
- Testing
- Alefacept, Methotrexate
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis
CC-292 is an oral agent that is under clinical development for the treatment of rheumatoid arthritis an autoimmune inflammatory disorder.
- Trial name
- NCT01975610
- Testing
- CC-292
- Where
- 27 sites in United States
- Volunteers
- 47 people
- Sponsor
- Celgene
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis
The 12-week core study was designed to evaluate risk-benefit of three subcutaneous dose regimens of ACZ885, added on to stable methotrexate (MTX) therapy (greater than or equal to 7.5 mg/week), compared to placebo in patients…
- Trial name
- NCT00424346
- Testing
- Canakinumab
- Where
- 17 sites in United States, Austria and 4 more
- Volunteers
- 274 people
- Sponsor
- Novartis
Active Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.
- Trial name
- NCT07409103
- Testing
- ELV001 25 mg, ELV001 75 mg, ELV001 125 mg
- Where
- 34 sites in United States, Serbia and 1 more
- Volunteers
- 180 people
- Sponsor
- Elevara Medicines Limited